Dijk, M.v.; Murphy, E.; Morrell, R.; Knapper, S.; O’Dwyer, M.; Samali, A.; Szegezdi, E.
The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis. Cancers 2011, 3, 1329-1350.
https://doi.org/10.3390/cancers3011329
AMA Style
Dijk Mv, Murphy E, Morrell R, Knapper S, O’Dwyer M, Samali A, Szegezdi E.
The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis. Cancers. 2011; 3(1):1329-1350.
https://doi.org/10.3390/cancers3011329
Chicago/Turabian Style
Dijk, Marianne van, Eoin Murphy, Ruth Morrell, Steven Knapper, Michael O’Dwyer, Afshin Samali, and Eva Szegezdi.
2011. "The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis" Cancers 3, no. 1: 1329-1350.
https://doi.org/10.3390/cancers3011329
APA Style
Dijk, M. v., Murphy, E., Morrell, R., Knapper, S., O’Dwyer, M., Samali, A., & Szegezdi, E.
(2011). The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis. Cancers, 3(1), 1329-1350.
https://doi.org/10.3390/cancers3011329